CNS and Neurological Disorders - Drug Targets

Aims & Scope

CNS & Neurological Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.

CNS & Neurological Disorders - Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets.

The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	3
2024	2.70

SJR (SCImago Journal Rank)

Year	Value
2024	0.710

Quartile

Year	Value
2024	Q2

h-index

Year	Value
2024	101

Journal Rank

Year	Value
2024	7955

Journal Citation Indicator

Year	Value
2024	832

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, Neuroscience and Pharmacology, Toxicology and Pharmaceutics, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities

  Citation: 511

  Authors: Ramon, Rodrigo, Rodrigo, Jose, Rodrigo, Andres, Walter

• Gliogenesis and Glial Pathology in Depression

  Citation: 489

  Authors: G., J.

• Clearance of Amyloid-β Peptide Across the Blood-Brain Barrier: Implication for Therapies in Alzheimers Disease

  Citation: 443

  Authors: R., R., A., B.

• The Endocannabinoid System and Pain

  Citation: 381

  Authors: Josee, Andrea

• Microglia and Inflammation in Alzheimers Disease

  Citation: 365

  Authors: Shweta, Gary E.

• Assessing Activation States in Microglia

  Citation: 334

  Authors: Carol A., Donna M.

• Effects of Exercise on Anxiety and Depression Disorders: Review of Meta- Analyses and Neurobiological Mechanisms

  Citation: 329

  Authors: Mirko, Ingo, Sergio, Antonio, Oscar, Henning

• Corticotropin Releasing Factor (CRF) Receptor Signaling in the Central Nervous System: New Molecular Targets

  Citation: 289

  Authors: Richard, Victoria, Olaf, Frank

• The Dopamine D3 Receptor: A Therapeutic Target for the Treatment of Neuropsychiatric Disorders

  Citation: 284

  Authors: L., E., C., O., B., J., P.

• Status of Acetylcholinesterase and Butyrylcholinesterase in Alzheimer's Disease and Type 2 Diabetes Mellitus

  Citation: 272

  Authors: Gohar, Nigel, Jalaluddin, Mohammad

---